IP Library Granted Patent US 9,387,217
Granted Patent B2
US 9,387,217 · App. 14/874,027 · Granted Jul 12, 2016

Acyclic nucleoside phosphonate diesters

Inventors: Karl Y. Hostetler (Del Mar, CA); James R. Beadle (San Diego, CA); Nadejda Valiaeva (San Diego, CA)
Assignee: The Regents of the University of California
A61K31/675C07F9/6561C07F9/65121C07F9/65616C07F9/65583
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,387,217
App. No.
14/874,027
Granted
Jul 12, 2016
Kind
B2
Abstract

The present disclosure relates, inter alia, to compositions and methods for treating viral diseases and cancer. There are disclosed lipophilic antiviral and anticancer acyclic nucleoside phosphonate diesters, preparation thereof, and methods of using the compounds to treat viral diseases and cancer.

Claims (13)

1. A method for treating an HPV viral infection in a host in need thereof comprising administering an effective amount of a compound of the formula:

or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

2. The method of claim 1 , wherein the viral infection is HPV 11.

3. The method of claim 1 , wherein the viral infection is HPV 16.

4. The method of claim 1 , wherein the viral infection is HPV 18.

5. The method of claim 1 , wherein the host is a human.

6. The method of claim 2 , wherein the host is a human.

7. The method of claim 3 , wherein the host is a human.

8. The method of claim 4 , wherein the host is a human.

9. The method of claim 5 , wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

10. The method of claim 6 , wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

11. The method of claim 7 , wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

12. The method of claim 8 , wherein the pharmaceutically acceptable carrier is suitable for topical delivery.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2015
From: HOSTETLER, KARL Y.; BEADLE, JAMES R.; VALIAEVA, NADEJDA
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 036719/0345 →
Continuity (4)
Continuation 14463908 · Aug 20, 2014
Continuation 14211235 · Mar 14, 2014
Provisional Application 61793993 · Mar 15, 2013
Related Publication 20160015726A1 · Jan 21, 2016